Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
1.
Reumatol Clin (Engl Ed) ; 20(5): 263-280, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38796394

RESUMEN

OBJECTIVE: To develop updated guidelines for the pharmacological management of rheumatoid arthritis (RA). METHODS: A group of experts representative of different geographical regions and various medical services catering to the Mexican population with RA was formed. Questions based on Population, Intervention, Comparison, and Outcome (PICO) were developed, deemed clinically relevant. These questions were answered based on the results of a recent systematic literature review (SLR), and the evidence's validity was assessed using the GRADE system, considered a standard for these purposes. Subsequently, the expert group reached consensus on the direction and strength of recommendations through a multi-stage voting process. RESULTS: The updated guidelines for RA treatment stratify various therapeutic options, including different classes of DMARDs (conventional, biologicals, and JAK inhibitors), as well as NSAIDs, glucocorticoids, and analgesics. By consensus, it establishes the use of these in different subpopulations of interest among RA patients and addresses aspects related to vaccination, COVID-19, surgery, pregnancy and lactation, and others. CONCLUSIONS: This update of the Mexican guidelines for the pharmacological treatment of RA provides reference points for evidence-based decision-making, recommending patient participation in joint decision-making to achieve the greatest benefit for our patients. It also establishes recommendations for managing a variety of relevant conditions affecting our patients.


Asunto(s)
Antirreumáticos , Artritis Reumatoide , Artritis Reumatoide/tratamiento farmacológico , Humanos , México , Antirreumáticos/uso terapéutico , Glucocorticoides/uso terapéutico , Femenino , Antiinflamatorios no Esteroideos/uso terapéutico , Embarazo , Analgésicos/uso terapéutico
2.
J Infect Dev Ctries ; 15(11): 1597-1602, 2021 11 30.
Artículo en Inglés | MEDLINE | ID: mdl-34898484

RESUMEN

INTRODUCTION: COVID-19 was declared a pandemic in March 2020, requiring a comprehensive response from all healthcare systems, including Mexico's. As medical residents' training did not involve epidemic response, we decided to evaluate their level of training on this subject, specifically self-perceived knowledge level and capacity to respond to epidemiological crises. METHODOLOGY: Medical residents from two hospitals belonging to PEMEX (Mexico's state-owned petroleum company) were included in a cross-sectional study. All participants answered a modified version of the survey developed by the University of Lovaina's Center for Research and Education in Emergency Care. Participants were analyzed according to their relevant "clinical" or "surgical" residency tracks. Data were analyzed using through Chi-square tests, t-tests, Mann-Whitney U tests, Kruskal-Wallis tests, and Pearson and Spearman correlation coefficients with significance established at p < 0.05. RESULTS: Of a total of 94 resident participants in this study, 56.7% self-perceived themselves as being poorly prepared to confront the pandemic. Only 25.5% of the participants referred previous experience in medical responses to public health emergencies, and only 35.1% reported ever receiving education on this topic. CONCLUSIONS: Medical residents-who have been involved with caring for victims of the pandemic-are under the general perception that they are not prepared, experienced, or educated enough to respond to such a widespread massive public health emergency.


Asunto(s)
COVID-19/epidemiología , Competencia Clínica , Internado y Residencia , SARS-CoV-2 , Autoimagen , Estudiantes de Medicina/psicología , Adulto , Estudios Transversales , Femenino , Humanos , Masculino , Cuerpo Médico de Hospitales , México/epidemiología , Pandemias , Encuestas y Cuestionarios
3.
Reumatol Clin (Engl Ed) ; 17(8): 440-446, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34625146

RESUMEN

OBJECTIVE: To determine the comorbidities associated with disability in patients with OA in Mexico (2013-2015). MATERIAL AND METHODS: A cross-sectional, retrospective and multicentre IMPACTAR study (n=7703) in Mexican patients (2013-2015). Comorbidities associated with disability were identified in 4971 patients diagnosed with OA from the IMPACTAR registry (n=7073). An adjusted logistic regression analysis was carried out by demographic, economic, clinical and medical variables. RESULTS: Mean age was 63 years; and 75% of the patients were women. Subjects with OA and presence of comorbidities are 42% more likely to develop disabilities than patients without associated comorbidity, considering age, sex, family income, OA diagnosis duration, and education level. The highest rate of people with disability (28.9%) was concentrated in Region 7, which corresponds to Mexico City. There are also significant differences between median family incomes, when the income of persons with disability is under $13 000 (IQR: 9000-16 000) Mexican pesos, compared to patients without disability. Almost half of the subjects (49.6%) reported having at least one comorbidity. Arterial hypertension was the risk factor with a statistically significant difference (32.8%) among those with disability (34.7%). CONCLUSIONS: Programs and interventions for OA patients should take into consideration comorbidity factors, being female, family income, and the region of residence as variables that may increase the possibility of developing an OA-associated disability.


Asunto(s)
Personas con Discapacidad , Osteoartritis , Comorbilidad , Estudios Transversales , Femenino , Humanos , México/epidemiología , Persona de Mediana Edad , Osteoartritis/epidemiología , Sistema de Registros , Estudios Retrospectivos
4.
Rev Esp Enferm Dig ; 113(8): 624-625, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-33569965

RESUMEN

In response to the kind letter from Joaquín Cabezas et al., we agree that medical care in the COVID era has radically changed and using new mechanisms in the care of different diseases is undoubtedly now a priority to avoid contagion of both the patient and the medical staff. Although a vaccine could protect the population, there are still many questions to answer. The model we use for the care of patients with a diagnosis of hepatitis C virus (HCV) in Mexico showed great benefits, as in other studies.


Asunto(s)
COVID-19 , Hepatitis C Crónica , Hepatitis C , Telemedicina , Antivirales/uso terapéutico , Hepacivirus , Hepatitis C/tratamiento farmacológico , Hepatitis C Crónica/tratamiento farmacológico , Humanos , México , SARS-CoV-2
5.
Rev. chil. infectol ; Rev. chil. infectol;37(4): 456-460, ago. 2020.
Artículo en Español | LILACS | ID: biblio-1138570

RESUMEN

Resumen Existe la percepción general de que los estudiantes de medicina deben ayudar en caso de situaciones de desastre o en contingencias epidemiológicas; aunque es posible que no hayan sido debidamente educados para hacerlo. En últimas fechas, la participación de estudiantes es importante en actividades de capacitación de personal, triage, atención de actividades burocráticas, voluntariado; pero no son considerados como una primera línea de atención en los sitios de desastre o de manejo de pacientes. Se revisa en la literatura médica la percepción de la participación de los estudiantes de medicina en desastres y pandemias y se establecen algunas de las necesidades para su capacitación y enseñanza, para que realmente puedan convertirse en una opción en los momentos de crisis.


Abstract There is a general perception that medical students should help in case of disaster situations or epidemiological contingencies; although, they may not have been properly educated to do so. In recent dates, the participation of students is important in staff training activities, triage, care of bureaucratic activities, volunteering; but they are not considered a first line of care at disaster sites or patient management. The perception of the participation of medical students in disasters and pandemics is reviewed in the literature and some of the needs for their training and teaching are established, so that they can truly become an option in times of crisis.


Asunto(s)
Humanos , Estudiantes de Medicina , Desastres , Triaje , Pandemias
6.
Artículo en Inglés, Español | MEDLINE | ID: mdl-32563732

RESUMEN

OBJECTIVE: To determine the comorbidities associated with disability in patients with OA in Mexico (2013-2015). MATERIAL AND METHODS: A cross-sectional, retrospective and multicentre IMPACTAR study (n=7703) in Mexican patients (2013-2015). Comorbidities associated with disability were identified in 4971 patients diagnosed with OA from the IMPACTAR registry (n=7073). An adjusted logistic regression analysis was carried out by demographic, economic, clinical and medical variables. RESULTS: Mean age was 63 years; and 75% of the patients were women. Subjects with OA and presence of comorbidities are 42% more likely to develop disabilities than patients without associated comorbidity, considering age, sex, family income, OA diagnosis duration, and education level. The highest rate of people with disability (28.9%) was concentrated in Region 7, which corresponds to Mexico City. There are also significant differences between median family incomes, when the income of persons with disability is under $13 000 (IQR: 9000-16 000) Mexican pesos, compared to patients without disability. Almost half of the subjects (49.6%) reported having at least one comorbidity. Arterial hypertension was the risk factor with a statistically significant difference (32.8%) among those with disability (34.7%). CONCLUSIONS: Programs and interventions for OA patients should take into consideration comorbidity factors, being female, family income, and the region of residence as variables that may increase the possibility of developing an OA-associated disability.

7.
Rev Chilena Infectol ; 37(4): 456-460, 2020 Aug.
Artículo en Español | MEDLINE | ID: mdl-33399667

RESUMEN

There is a general perception that medical students should help in case of disaster situations or epidemiological contingencies; although, they may not have been properly educated to do so. In recent dates, the participation of students is important in staff training activities, triage, care of bureaucratic activities, volunteering; but they are not considered a first line of care at disaster sites or patient management. The perception of the participation of medical students in disasters and pandemics is reviewed in the literature and some of the needs for their training and teaching are established, so that they can truly become an option in times of crisis.


Asunto(s)
Desastres , Estudiantes de Medicina , Humanos , Pandemias , Triaje
8.
J Med Ethics ; 45(12): 839-842, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31604831

RESUMEN

INTRODUCTION: Rheumatologists are the primary healthcare professionals responsible for patients with rheumatic diseases and should acquire medical ethical competencies, such as the informed consent process (ICP). The objective clinical structured examination is a valuable tool for assessing clinical competencies. We report the performance of 90 rheumatologist trainees participating in a station designed to evaluate the ICP during the 2018 and 2019 national accreditations. METHODS: The station was validated and represented a medical encounter in which the rheumatologist informed a patient with systemic lupus erythematosus with clinically active nephritis about renal biopsy. A trained patient-actor and an evaluator were instructed to assess ICP skills (with a focus on kidney biopsy benefits, how the biopsy is done and potential complications) in obtaining formal informed consent, delivering bad news and overall communication with patients. The evaluator used a tailored checklist and form. RESULTS: Candidate performance varied with ICP content and was superior for potential benefit information (achieved by 98.9% of the candidates) but significantly reduced for potential complications (37.8%) and biopsy description (42.2%). Only 17.8% of the candidates mentioned the legal perspective of ICP. Death (as a potential complication) was omitted by the majority of the candidates (93.3%); after the patient-actor challenged candidates, only 57.1% of them gave a clear and positive answer. Evaluators frequently rated candidate communications skills as superior (≥80%), but ≥1 negative aspect was identified in 69% of the candidates. CONCLUSIONS: Ethical competencies are mandatory for professional rheumatologists. It seems necessary to include an ethics competency framework in the curriculum throughout the rheumatology residency.


Asunto(s)
Acreditación , Competencia Clínica , Ética Médica , Reumatología/ética , Acreditación/métodos , Acreditación/normas , Biopsia/ética , Competencia Clínica/normas , Humanos , Consentimiento Informado/ética , Consentimiento Informado/normas , Riñón/patología , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/patología , México , Relaciones Médico-Paciente/ética , Reumatología/normas
9.
Med. interna Méx ; 35(3): 364-369, may.-jun. 2019. tab
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1154809

RESUMEN

Resumen: OBJETIVO: Evaluar la dosis acumulada ingerida de antiinflamatorios no esteroides (AINEs) en pacientes con úlcera péptica hemorrágica y sus complicaciones durante la hospitalización. MATERIAL Y MÉTODO: Estudio retrospectivo en el que de julio de 2015 a diciembre de 2017 se evaluaron dos grupos: uno con antecedente hospitalario de perforación, resangrado, reintervención endoscópica y muerte y otro sin complicaciones. Se ajustó la dosis ingerida de diferentes AINEs equivalente a 10 mg de ketorolaco; se registró el índice de Charlson, infección por H. pylori y la clasificación endoscópica de Forrest. RESULTADOS: Hubo 156 admisiones de úlcera péptica hemorrágica (edad promedio de 70 años, 53% hombres), las complicaciones ocurrieron en 53 (33.9%), la dosis promedio mensual de AINEs fue de 2121 mg (pacientes con complicaciones) vs 1970 mg (sin complicaciones; p = 0.2). La tasa de AINEs/semana de 7.1 se relacionó con perforación. A todos se les aplicó dosis de omeprazol de 40 mg cada 12 horas vía intravenosa durante la hospitalización. Las complicaciones se correlacionaron con mayor índice de Charlson. Hubo relación entre muerte, factores de riesgo de úlcera péptica por estrés (sepsis, traumatismo, etc.) y la administración de anticoagulantes. El tabaquismo y el género masculino se relacionaron con mayor resangrado. CONCLUSIONES: Existe mayor probabilidad de perforación con necesidad de cirugía, estancia hospitalaria más larga y mayor número de transfusiones con mayor dosis ingerida de AINEs.


Abstract: OBJECTIVE: To evaluate the cumulative dose of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with hemorrhagic peptic ulcer and their complications along hospitalization. MATERIAL AND METHOD: A retrospective study done from July 2015 to December 2017 including two groups: one with a hospitalization history of perforation, rebleeding, endoscopic reintervention and death, another group without complications. We registered doses of different NSAIDs according to 10 mg of ketorolac, Charlson index, H. pylori infection and endoscopic Forrest classification. RESULTS: There were 156 admissions of hemorrhagic peptic ulcer with the administration of NSAIDs (average age 70 years, 53% men), complications occurred in 53 (33.9%). The average monthly dose of NSAID in the cases was 2121 mg vs 1970 mg in controls. The NSAID/week rate of 7.1 was associated with perforation. Charlson index correlated with complications. Death and physiological stress related with the administration of anticoagulants. Smoking and the male gender related to higher rebleeding. CONCLUSIONS: The higher the NSAID/weekly rate, the higher the probability of perforation with the need for surgery, longer hospital stay and increased number of transfusions.

10.
Clin Rheumatol ; 38(10): 2709-2716, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31076944

RESUMEN

INTRODUCTION: Pain is a core complaint among rheumatoid arthritis (RA) patients, and persistent pain requires treatment adjustments according to current strategies. We aimed to quantify the impact of hand osteoarthritis (OA) on health status and residual pain in patients with RA. METHODS: This cross-sectional survey compared RA patients with and without osteoarthritis of the hand. The main outcome was pain intensity. Other measurements included disease activity scores (the Disease Activity Score 28-joints; the Simplified Disease Activity Index, SDAI; the Clinical Disease Activity Index, CDAI), functional disability and self-reported quality of life, and the proportion of patients with residual pain (Patient Acceptable Symptom State, PASS). RESULTS: Eighty-one patients were analyzed, including 39 with RA and OA and 42 with RA only. The patients were mainly women (94%), with a median disease duration of 13 years. This group also reported a higher intensity of pain (visual analogue scale, VAS 70 mm vs. 30 mm; p = 0.003), higher disease activity (3.89 vs. 2.88; p = 0.001), and greater functional disability irrespective of treatment and comorbidities. A strong correlation (r2 = 0.69; p < 0.001) between pain and disease activity was observed, although no differences in pain were observed between groups according to disease activity categories. Patients with RA and OA had a higher proportion of residual pain (59% vs. 29%; p = 0.006) even in the absence of clinical inflammation. CONCLUSION: The coexistence of RA and hand OA is associated with distorted disease activity measurements in RA. Osteoarthritis contributes to persistent pain and greater disability in patients with RA.


Asunto(s)
Artritis Reumatoide/complicaciones , Artritis Reumatoide/fisiopatología , Mano/fisiopatología , Osteoartritis/complicaciones , Osteoartritis/fisiopatología , Actividades Cotidianas , Anciano , Estudios Transversales , Femenino , Estado de Salud , Humanos , Masculino , Persona de Mediana Edad , Dolor/fisiopatología , Manejo del Dolor , Dimensión del Dolor , Calidad de Vida , Autoinforme , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Escala Visual Analógica
11.
Reumatol Clin (Engl Ed) ; 15(2): 97-101, 2019.
Artículo en Inglés, Español | MEDLINE | ID: mdl-28755908

RESUMEN

BACKGROUND: The Mexican Accreditation Council for Rheumatology annually certifies trainees in Rheumatology using a multiple-choice test and an objective structured clinical examination (OSCE). Since 2015, candidate's communication skills (CS) have been rated by both patients and by physician examiners and correlated with results on the OSCE. This study compared the CS from candidates to annual accreditation in Rheumatology as rated by patients and by physician examiners, and assessed whether these correlated with candidate's performance in the OSCE. MATERIAL AND METHODS: From 2015 to 2017, 8areas of CS were evaluated using a Likert scale, in each OSCE station that involved a patient. Both patient and physician evaluators were trained annually and their evaluations were performed blindly. The associations were calculated using the Pearson correlation coefficient. RESULTS: In general, candidates were given high CS scores; the scores from patients of the candidate's CS were better than those of physician examiners; within the majority of the stations, both scores were found to correlate moderately. In addition, the scoring of CS correlated with trainee performance at the corresponding OSCE station. Interestingly, better correlations were found when the skills were rated by the patients compared to physician scores. The average CS score was correlated with the overall OSCE performance for each trainee, but not with the multiple-choice test, except in the 2017 accreditation process, when a weak correlation was found. CONCLUSIONS: CS assessed during a national accreditation process correlated with the candidate's performance at the station level and with the overall OSCE.


Asunto(s)
Certificación/normas , Competencia Clínica/normas , Comunicación , Educación de Postgrado en Medicina/normas , Reumatología/educación , Humanos , México , Reumatología/normas
12.
Reumatol Clin (Engl Ed) ; 15(3): 133-139, 2019.
Artículo en Inglés, Español | MEDLINE | ID: mdl-28867467

RESUMEN

OBJECTIVE: To assess the efficacy and side effects of methotrexate and leflunomide in patients with rheumatoid arthritis (RA) as the first disease-modifying antirheumatic drug (DMARD). METHODS: We performed a systematic review and meta-analysis of clinical studies that included patients who took methotrexate, leflunomide, placebo or another DMARD for RA treatment. A systematic review yielded 1971 articles from databases; once completely reviewed, 73 trials that completed inclusion criteria were selected. In structured workshops for discussion and assessment of each article, 6 could be meta-analyzed for the primary and secondary outcomes: achievement of American College of Rheumatology (ACR) 20 and its core set components; and change of serum C-reactive protein (CRP) levels, Health Assessment Questionnaire Disability Index (HAQ-Di), liver enzyme aspartate transaminase/alanine transaminase ratio, new gastrointestinal (GI) side effects and infections. RESULTS: A total of 1984 patients were included: 986 took leflunomide and 998 methotrexate. The probability of achieving ACR 20 had an odds ratio (OR) of 0.88 (95% confidence interval [CI] 0.74, 1.06) with a trend toward favoring methotrexate; reduction of the swollen joint count was greater for methotrexate: mean difference=0.82 (95%CI 0.24, 1.39); tender joint count, physician global assessment, HAQ-Di, and serum CRP levels revealed no significant difference between groups. Increased liver enzymes were more frequent in the leflunomide group, OR=0.38 (95%CI 0.27, 0.53), and new GI complaints were more common with methotrexate (OR=1.44; 95%CI 1.17, 1.79). There was no difference in the incidence of non-severe infections. CONCLUSION: Leflunomide used as the first DMARD in RA seemed to be as efficacious as methotrexate; only the reduction of swollen joint count was more marked for methotrexate. Leflunomide was linked to a greater increase in liver enzymes, but there were fewer GI complaints.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Leflunamida/uso terapéutico , Metotrexato/uso terapéutico , Alanina Transaminasa/sangre , Antiinflamatorios no Esteroideos/efectos adversos , Antirreumáticos/efectos adversos , Aspartato Aminotransferasas/sangre , Proteína C-Reactiva/análisis , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Ensayos Clínicos como Asunto , Evaluación de la Discapacidad , Quimioterapia Combinada , Enfermedades Gastrointestinales/inducido químicamente , Humanos , Inmunosupresores/efectos adversos , Leflunamida/efectos adversos , Metotrexato/efectos adversos , Resultado del Tratamiento , gamma-Glutamiltransferasa/análisis
13.
Med. interna Méx ; 34(3): 443-476, may.-jun. 2018. tab, graf
Artículo en Español | LILACS | ID: biblio-976088

RESUMEN

Resumen La osteoartritis es una enfermedad articular crónica degenerativa, es la afección articular observada con más frecuencia en la población adulta y una de las principales causas de discapacidad en todo el mundo, por lo que es de importancia el diagnóstico y tratamiento en las fases tempranas de la enfermedad. En la actualidad los nuevos tratamientos, además de aliviar el dolor, pueden disminuir la limitación funcional y modificar el curso de la enfermedad. El objetivo de este artículo es actualizar la evidencia acerca del diagnóstico y de las nuevas formas de tratamiento de la osteoartritis, así como evaluar los cambios en la evidencia que ha habido en relación con la guía anterior. Para la elaboración de la guía motivo de esta reunión, se contó con la participación de especialistas en Medicina Interna, Reumatología, Ortopedia y Rehabilitación física, un bibliotecario y un experto en metodología; se realizó una búsqueda extensa en PubMed y en otros sitios web especializados. Se estableció una serie de recomendaciones y niveles de evidencia basados en la bibliografía consultada. Se concluye que la osteoartritis es una enfermead compleja que implica múltiples factores de riesgo, por lo que es importante tomar en cuenta que el tratamiento es multidisciplinario y consta de un enfoque no farmacológico y uno farmacológico; sin embargo, es necesario crear una cultura preventiva de la osteoartritis en los médicos tratantes, en la que se eduque y se dé información al paciente para evitar que la enfermedad progrese.


Abstract Osteoarthritis, a chronic degenerative joint disease, is the joint condition most frequently observed in the adult population; is one of the leading causes of disability worldwide. Therefore, it is important the diagnosis and treatment in the early stages of the disease. Currently new therapies, in addition to relieving pain, can reduce functional limitation and modify the course of the disease. The objective of this article is to update the evidence on diagnosis and new forms of osteoarthritis treatment, as well as to evaluate the changes in the evidence that has been in relation to the previous guide. For the elaboration of the guide, there was participation of specialists (Internal Medicine, Rheumatology, Orthopedics and Physical Rehabilitation), a librarian and an expert in methodology; an extensive search was carried out in PubMed and other specialized websites. A series of recommendations and levels of evidence were established based on the bibliography consulted. Concluding that osteoarthritis is a complex pathology involving multiple risk factors, it is important to consider that the treatment is multidisciplinary and consists of a non-pharmacological approach and a pharmacological treatment; however, it is necessary to create a preventive culture on osteoarthritis in treating doctors, in which the patient is educated and given information to prevent the disease from progressing.

14.
Reumatol Clin (Engl Ed) ; 14(3): 137-141, 2018.
Artículo en Inglés, Español | MEDLINE | ID: mdl-28161396

RESUMEN

BACKGROUND: The Mexican Accreditation Council for Rheumatology certifies trainees (TR) on an annual basis using both a multiple-choice question (MCQ) test and an objective structured clinical examination (OSCE). For 2013 and 2014, the OSCE pass mark (PM) was set by criterion referencing as ≥6 (CPM), whereas overall rating of borderline performance method (BPM) was added for 2015 and 2016 accreditations. We compared OSCE TR performance according to CPM and BPM, and examined whether correlations between MCQ and OSCE were affected by PM. METHODS: Forty-three (2015) and 37 (2016) candidates underwent both tests. Altogether, OSCE were integrated by 15 validated stations; one evaluator per station scored TR performance according to a station-tailored check-list and a Likert scale (fail, borderline, above range) of overall performance. A composite OSCE score was derived for each candidate. Appropriate statistics were used. RESULTS: Mean (±standard derivation [SD]) MCQ test scores were 6.6±0.6 (2015) and 6.4±0.6 (2016) with 5 candidates receiving a failing score each year. Mean (±SD) OSCE scores were 7.4±0.6 (2015) and 7.3±0.6 (2016); no candidate received a failing CPM score in either 2015 or 2016 OSCE, although 21 (49%) and 19 (51%) TR, respectively, received a failing BPM score (calculated as 7.3 and 7.4, respectively). Stations for BPM ranged from 4.5 to 9.5; overall, candidates showed better performance in CPM. In all, MCQ correlated with composite OSCE, r=0.67 (2015) and r=0.53 (2016); P≤.001. Trainees with a passing BPM score in OSCE had higher MCQ scores than those with a failing score. CONCLUSIONS: Overall, OSCE-PM selection impacted candidates' performance but had a limited affect on correlation between clinical and practical examinations.


Asunto(s)
Rendimiento Académico/normas , Certificación/normas , Competencia Clínica/normas , Educación de Postgrado en Medicina/normas , Evaluación Educacional/normas , Reumatólogos/educación , Evaluación Educacional/métodos , Humanos , México , Reumatología/educación
15.
Rev Med Inst Mex Seguro Soc ; 53(3): 274-8, 2015.
Artículo en Español | MEDLINE | ID: mdl-25984611

RESUMEN

BACKGROUND: It is unknown which analgesic modality gives better results after a laparoscopic cholecystectomy. The aim of this study was to compare the analgesic efficacy of ropivacaine for local use against that of intravenous dipyrone in laparoscopic cholecystectomy. METHODS: A non-inferiority randomized clinical trial. Fifty patients with laparoscopic cholecystectomy were included into two separate groups. INTERVENTION: 0.75 % ropivacaine infiltrated at the trocar insertion sites and in the gallbladder fossa compared with intravenous dipyrone. MEASUREMENTS: The primary outcome was pain, which was assessed using the visual analog scale during the first 24 hours. Secondary outcomes were the presence of adverse effects, and the need for analgesic rescue with tramadol. RESULTS: The visual analog scale average for pain at the conclusion of the surgery was 3.8 in the ropivacaine vs. 3.56 in the dipyrone groups, while at 6, 12 and 24 hours the values were 2.64, 1.92 and 1.28, respectively, for ropivacaine versus 2.6, 1.88 and 1.2, respectively, for dipyrone. No adverse effects were observed in either group, and the two groups exhibited similar needs for analgesic rescue with tramadol. CONCLUSIONS: Infiltration of 0.75 % ropivacaine at the trocar insertion sites and the gallbladder exhibits analgesia similar to IV dipyrone during the first 24 hours post-laparoscopic cholecystectomy without adverse effects.


Introducción: se desconoce qué modalidad analgésica brinda mejores resultados después de una colecistectomía laparoscópica. El objetivo de este estudio consistió en valuar la eficacia analgésica de la ropivacaína usada localmente contra la dipirona por vía intravenosa en colecistectomía laparoscópica. Métodos: ensayo clínico al azar, de no inferioridad, en 50 pacientes con colecistectomía laparoscópica para comparar el uso de ropivacaína al 0.75 % infiltrada en el lugar de inserción de los trócares y en la fosa vesicular frente a dipirona por vía intravenosa. El desenlace primario fue dolor evaluado mediante escala visual análoga (EVA) en las primeras 24 horas. Resultados: el promedio de las EVA de dolor al término de la cirugía fue de 3.8 frente a 3.56 en el grupo de ropivacaína o de dipirona, mientras que a las 6, 12 y 24 horas fueron 2.64 frente a 2.6, 1.92 frente a 1.88 y 1.28 frente a 1.2, respectivamente. No hubo efectos adversos en ningún grupo y la necesidad de rescates analgésicos con tramadol fue similar entre ambos grupos. Conclusiones: la ropivacaína al 0.75 % infiltrada en el lugar de inserción de los trócares y la fosa vesicular muestra una analgesia similar a la dipirona por vía intravenosa en las primeras 24 horas después de una colecistectomía laparoscópica, sin efectos adversos.


Asunto(s)
Amidas/administración & dosificación , Anestésicos Locales/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Colecistectomía Laparoscópica , Dipirona/administración & dosificación , Dolor Postoperatorio/prevención & control , Administración Tópica , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Amidas/uso terapéutico , Anestésicos Locales/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Dipirona/uso terapéutico , Esquema de Medicación , Femenino , Humanos , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Ropivacaína , Resultado del Tratamiento , Adulto Joven
16.
Reumatol Clin ; 11(4): 215-20, 2015.
Artículo en Inglés, Español | MEDLINE | ID: mdl-25523985

RESUMEN

OBJECTIVE: To assess reliability and validity of the objectively-structured clinical examination (OSCE) applied in postgraduate certification processes by the Mexican Board of Rheumatology. METHOD: Thirty-two (2013) and 38 (2014) Rheumatology trainees (RTs) underwent an OSCE consisting of 12 and 15 stations respectively, scored according to a validated check-list, as well as 300-multiple-choice 300 question examination (MCQ). Previously, 3 certified rheumatologists underwent a pilot-OSCE. A composite OSCE score was obtained for each participant and its performance examined. RESULTS: In 2013, OSCE mean score was 7.1±0.6 with none RT receiving a failing score while the MCQ score was 6.5±0.6 and 7 (21.9%) RTs receiving a failing (< 6) score. In 2014, the OSCE score was 6.7±0.6, with 3 (7.9%) RTs receiving a failing score (2 of them also failed MCQ) while the MCQ score was 6.4±0.5 and 7 (18.5%) RTs were disqualified (2 of them also failed OSCE). A significant correlation between the MCQ and the OSCE scores was observed in the 2013 (r=0.44; P=0.006). Certified rheumatologists performed better than RTs at both OSCE. Overall, 86% of RTs obtaining an OSCE passing score also obtained a MCQ passing score, while this was only 67% (P=.02) among those who obtained an OSCE failing score. Nine stations were applied at both consecutive years. Their performance was similar in both certification processes, with correlation coefficients ranging from 0.81 to 0.95 (P≤0.01). CONCLUSION: The OSCE is a valid and reliable tool to assess the Rheumatology clinical skills in RTs.


Asunto(s)
Certificación/normas , Educación de Postgrado en Medicina/normas , Evaluación Educacional/métodos , Reumatología/educación , Competencia Clínica/normas , Evaluación Educacional/normas , Humanos , México , Reproducibilidad de los Resultados , Reumatología/normas
17.
J Clin Densitom ; 17(4): 484-9, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24613450

RESUMEN

Cost-minimization study to assess the annual direct costs of 2 antiresorptive strategies in postmenopausal women with low bone mineral densities (BMDs). Patients were randomly assigned to receive 70 mg of oral weekly alendronate or a 1-time 5mg of intravenous zoledronic acid. All medical and nonmedical direct costs were recorded for 1 yr. Student's t-test or the Chi-squared test was used. A total of 101 postmenopausal women were enrolled with a mean age of 58.3 ± 7.6 yr and a postmenopausal period of 13.5 ± 8.3 yr. A total of 50 patients completed 1 yr of alendronate and 51 patients received zoledronic acid. At baseline, no differences were seen between the 2 groups in anthropometric measures, comorbidities, and bone mineral density. The costs for medical attention for low bone mass were $81,532 (US Dollars) for the alendronate group and $69,251 for the zoledronic acid group; the cost per patient was $1631 in the alendronate group vs $1358 in the zoledronic acid group (p<0.0001). Therefore, zoledronic acid treatment provided an annual savings of 15% of the direct costs compared with oral alendronate treatment. Moreover, there was a significant increase in lumbar spine T-scores in the zoledronic acid group when compared with the alendronate group. Annual zoledronic acid infusion as an antiresorptive treatment in women with low BMD provides significant monetary savings when compared with weekly alendronate therapy for 1 yr. Zoledronic acid infusion is also linked to higher increase in BMD and compliance.


Asunto(s)
Alendronato/administración & dosificación , Conservadores de la Densidad Ósea/administración & dosificación , Conservadores de la Densidad Ósea/economía , Densidad Ósea/efectos de los fármacos , Difosfonatos/administración & dosificación , Imidazoles/administración & dosificación , Osteoporosis Posmenopáusica/tratamiento farmacológico , Absorciometría de Fotón , Administración Oral , Anciano , Alendronato/economía , Carbonato de Calcio/administración & dosificación , Carbonato de Calcio/economía , Control de Costos , Difosfonatos/economía , Esquema de Medicación , Femenino , Humanos , Imidazoles/economía , Infusiones Intravenosas , Persona de Mediana Edad , Osteoporosis Posmenopáusica/diagnóstico por imagen , Estudios Prospectivos , Resultado del Tratamiento , Vitamina D/administración & dosificación , Vitamina D/economía , Ácido Zoledrónico
18.
Reumatol Clin ; 9(2): 113-6, 2013.
Artículo en Inglés, Español | MEDLINE | ID: mdl-23395225

RESUMEN

Biotechnological drugs (BTDs) are complex molecules whose manufacturing process precludes the ability to identically reproduce the structure of the original product, and therefore there cannot be an absolute equivalence between the original (innovative) medication and its biosimilar counterpart. BTDs have been proven useful in the treatment of several rheumatic diseases, however their high cost has prevented their use in many patients. Several BTD patents have expired or are close to expire, triggering the development of structurally similar drugs with efficacy and safety profiles comparable to the innovative compound; however, these must be evaluated through evidence based medicine. The Mexican General Health Law contemplates the registry of these biosimilar drugs for their use in our country. This document is a forethought from members of the Mexican College of Rheumatology, pharmacologists, and epidemiologists, in accordance with Mexican health authorities regarding the necessary scientific evidence required to evaluate the efficacy and safety of biosimilar drugs before and after their arrival to the Mexican market.


Asunto(s)
Antirreumáticos/uso terapéutico , Biosimilares Farmacéuticos/uso terapéutico , Aprobación de Drogas , Farmacovigilancia , Enfermedades Reumáticas/tratamiento farmacológico , Aprobación de Drogas/legislación & jurisprudencia , Humanos , México
19.
Arch Med Res ; 38(3): 354-9, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17350489

RESUMEN

BACKGROUND: We undertook this study to describe prescription practices and the degree of disease control in a large sample of patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) treated by rheumatologists in Mexico. METHODS: Board-certified Mexican rheumatologists across the country were asked to assess consecutive RA and AS patients; 1208 patients completed a self-administered questionnaire with information on demographics, disease duration, co-morbidity, treatment, pain, disability and a validated Spanish version of instruments to measure physical function and quality of life. RESULTS: Of the 1096 RA patients, 88.1% were treated with nonsteroidal anti-inflammatory drugs (NSAIDs), 1020 (93.3%) with disease-modifying anti-rheumatic drugs (DMARDs), 365 (33.4%) with steroids, and 70 (6.4%) with biological agents. Their mean Health Assessment Questionnaire Disability Index (HAQ-Di) score was 1.21+/-0.80, Disease Activity Index, 28 joint count (DAS 28) 3.9+/-1.29, and Rheumatoid Arthritis Disease Activity Index (RADAI), 3.94+/-2.01. Regarding the 112 AS patients, 110 (98.2%) received NSAIDs, 90 (80.4%) were on DMARDs, 11 (9.8%) took steroids, and 11 (9.8%) received biological agents, their functional status shown as Bath Ankylosing Spondylitis Functional Index (BASFI) score of 4.4+/-2.5. Among the 1110 DMARD users, only 64 received one drug, and a great proportion used two or more DMARDs; 81 subjects (16.2%) were on biological agents, in any combination. RA patients more commonly used methotrexate, 791 (72%) cases, and hydroxychloroquine. Taking into account their diagnosis, the combination most prescribed was NSAIDs plus DMARDs in 660 subjects (54.7%). CONCLUSIONS: DMARDs in combination with other drug are the most frequently prescribed therapeutic scheme for RA and AS patients. These schemes used for both conditions by Mexican rheumatologists are in line with current international recommendations.


Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Prescripciones de Medicamentos , Médicos , Pautas de la Práctica en Medicina , Espondilitis Anquilosante/tratamiento farmacológico , Adulto , Estudios Transversales , Evaluación de la Discapacidad , Quimioterapia Combinada , Utilización de Medicamentos , Femenino , Humanos , México , Persona de Mediana Edad , Calidad de Vida , Reumatología , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios
20.
Rev. invest. clín ; Rev. invest. clín;57(6): 762-769, Nov.-Dec. 2005. tab
Artículo en Inglés | LILACS | ID: lil-632394

RESUMEN

Background. Causes of FUO change according to medical innovations, modifications of social circumstances, and emerging health risks. Aim. To describe the epidemiology of classical FUO, the time and procedures to achieve a definitive diagnosis, and to underline the variables useful in distinguishing FUO categories. Setting. A third-referral center in Mexico City. Methods. Patients admitted with prolonged fever were evaluated. Clinical charts of patients with classical FUO were assessed; comparisons between classical FUO categories were made. Results. 45 patients with 44.9 ± 17.2 years of age, previous fever duration of 51.2 ± 51.5 days, and 88.9% referred from other hospitals were evaluated. Nineteen patients had infectious causes; eight, neoplastic conditions; 12, inflammatory non-infectious diseases; one had another cause, and five were discharged with no etiologic diagnosis. Age, LDH levels, length of fever, and weight loss greater than 10 kg may be used to classify patients into a definite category. Conclusions. Classical FUO is an unusual presentation of frequent infectious diseases; SLE is the main cause within the inflammatory non-infectious conditions, and non-Hodgkin's lymphoma is the first cause of cancer. Some clinical and laboratory clues may be used to guide the study work up of patients with classical FUO.


Las causas de fiebre de origen indeterminado (FOI) varían de acuerdo con las innovaciones médicas o con modificaciones de las circunstancias sociales y riesgos para la salud. Objetivo. Describir la epidemiología de la FOI, el tiempo y procedimientos empleados para alcanzar un diagnóstico definitivo y evaluar las variables que pueden usarse para diferenciar sus categorías. Hospital. Centro de referencia de tercer nivel de la ciudad de México. Métodos. Se evaluó a pacientes con fiebre prolongada; los expedientes clínicos de aquellos con FOI fueron analizados y se compararon sus principales categorías. Resultados. Fueron evaluados 45 pacientes, de 44 ± 17.2 años de edad y duración promedio de la fiebre de 51.2 ± 51.5 días, de los cuales 88.9% habían sido referidos de otros hospitales. De ellos, 19 fueron diagnosticados con causas infecciosas, ocho con enfermedades neoplá-sicas, 12 con enfermedades inflamatorias no infecciosas, uno por alguna otra causa y cinco fueron dados de alta sin diagnóstico definitivo. La edad, niveles de DHL, la duración de la fiebre y la pérdida de peso mayor de 10 kg fueron marcadores útiles para clasificar a los pacientes en alguna de las categorías de la FOI. Conclusiones. La FOI es una manifestación inusual de enfermedades infecciosas frecuentes, el lupus erítematoso generalizado es la causa principal dentro de las condiciones inflamatorias no infecciosas y el línfoma no-Hodgkin en las neoplásicas. Algunas pistas clínicas y de laboratorio pueden emplearse para guiar el estudio de pacientes con FOI clásica.


Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fiebre de Origen Desconocido/epidemiología , Factores de Edad , Alanina Transaminasa/sangre , Fosfatasa Alcalina/sangre , Aspartato Aminotransferasas/sangre , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/epidemiología , Biomarcadores , Fiebre de Origen Desconocido/etiología , Hospitales Especializados/estadística & datos numéricos , Infecciones/complicaciones , Infecciones/diagnóstico , Infecciones/epidemiología , Inflamación/complicaciones , Inflamación/diagnóstico , Inflamación/epidemiología , L-Lactato Deshidrogenasa/sangre , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/epidemiología , Linfoma no Hodgkin/complicaciones , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/epidemiología , México/epidemiología , Neoplasias/complicaciones , Neoplasias/diagnóstico , Neoplasias/epidemiología , Derivación y Consulta
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA